Figure 2.
OS (measured from randomization at start of maintenance; data cut-off, 4 June 2021) in key subgroups of the JAVELIN Bladder 100 trial, including patients who received first-line chemotherapy with (A) cisplatin + gemcitabine or (B) carboplatin + gemcitabine,70 and patients whose best response to first-line chemotherapy was (C) complete response, (D) partial response, or (E) stable disease.78
BSC, best supportive care; CI, confidence interval; HR, hazard ratio; NE, not estimable; OS, overall survival.